Miyamoto, Brigitta E <br/><br/>
The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases.  [electronic resource] 

 -  Orphanet journal of rare diseases  Jul 2011 
 - 49 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1750-1172 
<br/><br/><label>Standard No.: </label>10.1186/1750-1172-6-49  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Biomarkers<br/>Biotechnology--economics<br/>Clinical Trials as Topic<br/>Drug Approval--legislation & jurisprudence<br/>Humans<br/>Orphan Drug Production--economics<br/>Outcome Assessment, Health Care<br/>Rare Diseases--drug therapy<br/>United States<br/>United States Food and Drug Administration